The unintended outcomes and the failed MS trials with anti-TNF-α therapies could be explained by the pleiotropic effects of TNF-α and the different downstream effects of TNFR1 and TNFR2 blockage. This evidence concerns the gene TNFRSF1B and myeloid sarcoma.